Avalon GloboCare announced Thursday that CEO David Jin will unveil the launch of the company’s new commercialization plan for its exosome...
Read More »Lung Cancer Liquid Biopsy Market Size Estimated to Observe Significant Growth
Liquid biopsy is a non-invasive substitute to surgical biopsies for the detection of molecular biomarkers. Liquid biopsy forms an integral part of precision...
Read More »Evolution of the Exosomes Market Landscape
Research on Exosomes/Extracellular Vesicles Is Growing and Focusing on Their Potential as Circulating Biomarkers for Liquid Biopsy Development from Genetic Engineering News by Gary Oosta, Ph.D. & Enal Razvi, Ph.D. Select Biosciences has been tracking the exosomes landscape for the ...
Read More »Exosome cancer diagnostic reaches market
The first blood-based cancer diagnostic to exploit free-floating exosomes became commercially available in the US on January 21. The launch of this ‘liquid biopsy’ from Exosome Diagnostics of Cambridge, Massachusetts, marks a step towards maturity for the fledgling science of ...
Read More »